Biogen Inc (BIIB.OQ)
15 Dec 2017
Mon, Dec 4 2017
* BIOGEN APPOINTS MARK HERNON AS SVP, CHIEF INFORMATION OFFICER Source text for Eikon: Further company coverage:
* SARISSA CAPITAL MANAGEMENT'S ALEXANDER DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING Source text: (http://bit.ly/2niyLpi) Further company coverage:
Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.
Nov 27 Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.
* Appoints Jeff Capello as executive vice president and chief financial officer
* Acorda announces royalty monetization transactions for $53 million
* Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab
Biogen Inc's shares dived 8 percent on Tuesday after U.S. sales of Spinraza, a potential blockbuster drug it is banking on to offset slowing sales of multiple sclerosis drugs, fell short of Wall Street estimates in the latest quarter.
* Shares fall as much as 8.14 pct in early trading (Adds details of payment to Neurimmune related to Aducanumab, updates shares)
* Biogen Inc - company restructures collaboration arrangements with eisai and neurimmune to improve long-term value of aducanumab
- Biotech In 2018: Will Repatriated Cash Fuel A Feeding Frenzy?
- Valuation Dashboard: Healthcare - Update
- Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars
- Looking For Top Stocks In The Strongest Performing Sectors
- Daily Insider Ratings Round Up 11/30/17: BIIB, CLRO, MDCO, TWTR, ADC, MSF, KW
- Your Daily Pharma Scoop: Dynavax Beyond Heplisav-B, Novartis' Cosentyx, Shire Granted ODD